Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) a...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court. The settlement follows a victory for Gilead in a 2023 jury trial on the government's patent infringement allegations. Gilead General Counsel Deborah Telman said in a statement that the agreement "allows Gilead to continue to focus its resources on its mission to discover, develop, and deliver innovative therapeutics to people with life-threatening diseases."
Global Financial Private Client LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,222.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,068 shares of the biopharmaceutical company'
